drugset / Trial / NCT03517995
Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention
Phase 2
Withdrawn
H. Lee Moffitt Cancer Center and Research Institute
Johns Hopkins University · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The main purpose of this study is to see if Prostaphane is effective and can help reduce the progression of bladder cancer. Researchers also want to find out if Prostaphane is safe and tolerable, and to evaluate how Prostaphane works to reduce the progression of bladder cancer. This study will compare Prostaphane with a placebo to see if taking Prostaphane is better than taking a placebo. A placebo is a pill that looks like Prostaphane but has no drug or other active ingredients in it. The study will be presented to eligible patients by the patient's surgeon at the time when an appointment is made for cystoscopy for suspicion of bladder cancer (BC) or to confirm BC diagnosis.
Timeline
- Start
- 2020-04
- Primary completion
- 2021-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sulforaphane | Small molecule | 10 mg | — |